Complete response of leptomeningeal carcinomatosis secondary to breast cancer
Related Experiment Video
Updated: Nov 27, 2025
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Idriss Troussier1, Charles Canova2, Guillaume Klausner3
1Radiation Oncology Department, Hospital Universitary of Geneva, Avenue de La Roseraie 53, 1205, Genève, Suisse, Switzerland; Radiation Oncology Department, Centre de Haute Energie, 10 Boulevard Pasteur, 06000, Nice, France.
Abstract:
Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4-6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown. Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy.
